Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31324731 | 0.82 | — | — | |
| SCHEMBL23375328 | 0.80 | HCAR2 (0.43) | ALDH1A1LMNAHSD17B10HCAR2SMN1; SMN2 | |
| SCHEMBL27739897 | 0.80 | CYP2C9 (0.35) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL10275655 | 0.79 | ALDH1A1 (0.46) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL31324755 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL31324766 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL16357720 | 0.78 | ALDH1A1 (0.40) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL13312880 | 0.78 | ALDH1A1 (0.35) | ALDH1A1LMNAHSD17B10ALOX15MGAM | |
| SCHEMBL524836 | 0.77 | — | — | |
| SCHEMBL28230301 | 0.77 | ALDH1A1 (0.43) | ALDH1A1LMNAHSD17B10ALOX15MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 668 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113943334-B | A, A 2A Process for preparing adenosine receptor agonists | 常州方圆制药有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117430647-A | Preparation method of regadenoson | 康普药业股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| WO-2024007890-A1 | METHOD FOR PREPARING RUXOLITINIB INTERMEDIATE | 济宁学院 | 2024-01-11 | — | — | WO | claimed |
| CN-115141180-B | Preparation method of ruxotinib intermediate | 济宁学院 | 2023-06-20 | — | — | CN | claimed |
| CN-116023331-A | Synthesis method of 3- (difluoromethyl) -1-methyl-1H-pyrazole-4-carboxylic acid | 馨仝(上海)生物科技有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-110483602-B | Preparation method of regadenoson | 常州方圆制药有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-113943334-A | A2AAdenosine receptor agonists | 常州方圆制药有限公司 | 2022-01-18 | — | — | CN | claimed |
| CN-113004208-A | Compound for inhibiting xanthine oxidase activity and preparation method and application thereof | 沈阳药科大学 | 2021-06-22 | — | — | CN | claimed |
| CN-110078747-B | Novel thiazole drug molecule for hospital disinfection and preparation method thereof | 河南科技大学第一附属医院 | 2020-04-10 | — | — | CN | claimed |
| US-20160244474-A1 | PROCESS OF MAKING REGADENOSON AND NOVEL POLYMORPH THEREOF | APICORE US LLC (US) | 2016-08-25 | — | — | US | claimed |
| US-20110144320-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | GILEAD PALO ALTO, INC. | 2011-06-16 | — | — | US | claimed |
| US-7956179-B2 | Process for preparing an A2A-adenosine receptor agonist and its polymorphs | GILEAD SCIENCES, INC. (US) | 2011-06-07 | — | — | US | claimed |
| US-20100179313-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | GILEAD PALO ALTO, INC. | 2010-07-15 | — | — | US | claimed |
| US-7732595-B2 | (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide; stable under relative humidity stress | GILEAD PALO ALTO, INC. (US) | 2010-06-08 | — | — | US | claimed |
| EP-2158208-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV Therapeutics Inc. (US) | 2010-03-03 | — | — | EP | claimed |
| WO-2008143667-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | WO | claimed |
| EP-1989214-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV THERAPEUTICS, INC. (US) | 2008-11-12 | — | — | EP | claimed |
| US-20070265445-A1 | (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide; stable under relative humidity stress | GILEAD SCIENCES, INC. | 2007-11-15 | — | — | US | claimed |
| US-20070225247-A1 | (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide; stable under relative humidity stress | GILEAD SCIENCES, INC. | 2007-09-27 | — | — | US | claimed |
| WO-2007092372-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | CV THERAPEUTICS, INC. (US) | 2007-08-16 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265445-A1 | (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide; stable under relative humidity stress | ADORA2A, ADORA3, ADORA2B | ALDH1A1 763/4885LMNA 2195/4885HSD17B10 4712/4885 |
| US-20110144320-A1 | N-PYRAZOLE A2A RECEPTOR AGONISTS | ADORA2A, ADORA3, TBXA2R | ALDH1A1 1264/4885LMNA 3247/4885HSD17B10 3993/4885 |
| US-20160244474-A1 | PROCESS OF MAKING REGADENOSON AND NOVEL POLYMORPH THEREOF | ADORA3, ADORA2A, ADA | ALDH1A1 968/4885LMNA 1967/4885HSD17B10 2143/4885 |
| US-20100179313-A1 | PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS | ADORA2A, ADORA3, ADORA2B | ALDH1A1 1160/4885LMNA 1780/4885HSD17B10 3772/4885 |
| US-20070225247-A1 | (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide; stable under relative humidity stress | ADORA2A, ADORA3, ADORA2B | ALDH1A1 763/4885LMNA 2195/4885HSD17B10 4712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.